AKTOCYTE Tablets
Scientists from the Department of Atomic Energy and IDRS Labs Pvt. Ltd. Bengaluru have developed AKTOCYTE tablets, designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator, and antioxidant. The primary aim of this collaboration is to minimize the side effects of radiotherapy, particularly in pelvic cancer patients suffering from radiotherapy-induced Cystitis. The tablets have shown remarkable results, eliminating the need for surgical removal of the urinary bladder. The tablets are expected to hit the market in January 2024.
